Lower glycemic indices and lipid profile among type 2 diabetes mellitus patients who received novel dose of Silybum marianum (L.) Gaertn. (silymarin) extract supplement: A Triple-blinded randomized controlled clinical trial.

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

This randomized clinical trial was conducted to evaluate the effects of silymarin supplementation on glycemic indices and serum lipid profile in type 2 diabetes mellitus (T2DM) patients.

Who Took Part

The abstract describes 40 patients taking part.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

40 T2DM patients (twenty male and twenty female), 25-50 years of age and on stable medication, were recruited for the present paralleled, randomized, triple-blinded, placebo-controlled clinical trial.

How the Study Was Run

The researchers set it up as a randomized, placebo-controlled and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

Groups ran in parallel: each of the patients stayed in one arm throughout.

Anthropometric and dietary intake data were collected at the baseline and end of the trial.

Fasting blood samples were collected, and glycemic indices and lipid profile were determined at baseline, as well as the end of the study.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Cholesterol, LDL, Diabetes Mellitus, Type 2, Dietary Supplements, Glycemic Index, Insulin Resistance and Lipids.

Author keywords: Hyperglycemia, Serum lipids and Silymarin.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and parallel-group study of Copper (Supplement) in 40 patients.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Phytomedicine : international journal of phytotherapy and phytopharmacology), a journal based in Germany.

More context: the Copper (Supplement) compound page, all human trials.